BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1329 related articles for article (PubMed ID: 19361748)

  • 1. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.
    Koh LP; Chao NJ
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):1-22. PubMed ID: 14752775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of pediatric allogeneic hematopoietic-cell transplantation.
    Majhail NS; Mothukuri JM; Macmillan ML; Verneris MR; Orchard PJ; Wagner JE; Weisdorf DJ
    Pediatr Blood Cancer; 2010 Jan; 54(1):138-43. PubMed ID: 19693941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
    Bautista G; Regidor C; Gonzalo-Daganzo R; Cabrera JR
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():47-51. PubMed ID: 21381288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).
    Arora M; Nagaraj S; Wagner JE; Barker JN; Brunstein CG; Burns LJ; Defor TE; McMillan ML; Miller JS; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1145-52. PubMed ID: 17889350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
    Johnston L
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.
    Jacobsohn DA; Hewlett B; Ranalli M; Seshadri R; Duerst R; Kletzel M
    Bone Marrow Transplant; 2004 Nov; 34(10):901-7. PubMed ID: 15361908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Umbilical cord blood as a source of stem cells].
    Bojanić I; Golubić Cepulić B
    Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
    Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
    Malard F; Milpied N; Blaise D; Chevallier P; Michallet M; Lioure B; Clément L; Hicheri Y; Cordonnier C; Huynh A; Yakoub-Agha I; Peffault de Latour R; Mohty M
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS; Challa TR; Mulrooney DA; Baker KS; Burns LJ
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
    van Heeckeren WJ; Fanning LR; Meyerson HJ; Fu P; Lazarus HM; Cooper BW; Tse WW; Kindwall-Keller TL; Jaroscak J; Finney MR; Fox RM; Solchaga L; Forster M; Creger RJ; Laughlin MJ
    Br J Haematol; 2007 Nov; 139(3):464-74. PubMed ID: 17910637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
    Ballen KK; Joffe S; Brazauskas R; Wang Z; Aljurf MD; Akpek G; Dandoy C; Frangoul HA; Freytes CO; Khera N; Lazarus HM; LeMaistre CF; Mehta P; Parsons SK; Szwajcer D; Ustun C; Wood WA; Majhail NS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
    Gorak E; Geller N; Srinivasan R; Espinoza-Delgado I; Donohue T; Barrett AJ; Suffredini A; Childs R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):542-50. PubMed ID: 15983554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.